Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin Chiu Yuen Chow

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The AAPS Journal|August 14, 2016
Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity AnalysesEdwin Chiu Yuen Chow, Arjang Talattof, Eleftheria Tsakalozou, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2008
A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibitionHuadong Sun, Li Zhang, Edwin Chiu Yuen Chow, et al.
Drugs in R&D|September 11, 2020
Comparability Considerations and Challenges for Expedited Development Programs for Biological ProductsSarah J Schrieber, Wendy S Putnam, Edwin Chiu Yuen Chow, et al.
Clinical and Translational Science|September 6, 2022
Human radiolabeled mass balance studies supporting the FDA approval of new drugsAnuradha Ramamoorthy, Girish Bende, Edwin Chiu Yuen Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2023
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 MutationAshley Woods, Kelly J Norsworthy, Xin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2022
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 MutationSandra J Casak, Shan Pradhan, Lola A Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The AAPS Journal|August 14, 2016
Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity AnalysesEdwin Chiu Yuen Chow, Arjang Talattof, Eleftheria Tsakalozou, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2008
A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibitionHuadong Sun, Li Zhang, Edwin Chiu Yuen Chow, et al.
Drugs in R&D|September 11, 2020
Comparability Considerations and Challenges for Expedited Development Programs for Biological ProductsSarah J Schrieber, Wendy S Putnam, Edwin Chiu Yuen Chow, et al.
Clinical and Translational Science|September 6, 2022
Human radiolabeled mass balance studies supporting the FDA approval of new drugsAnuradha Ramamoorthy, Girish Bende, Edwin Chiu Yuen Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2023
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 MutationAshley Woods, Kelly J Norsworthy, Xin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2022
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 MutationSandra J Casak, Shan Pradhan, Lola A Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Pageof 1